X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.393 0.0036 (0.92%) Market Cap: 67.03 Mil Enterprise Value: 10.25 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 30/100

X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 07:45PM GMT
Release Date Price: $1.6 (-8.57%)
Gil Blum
Needham & Company, LLC - Analyst

Good afternoon, everybody. My name is Gil Blum, and I am a senior analyst at Needham and Company covering companies particularly in oncology space. It is my pleasure to have Paula Ragan here from X4 with me, and she will discuss X4's recent progress and clinical programs. Paula?

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

Thanks so much, Gil. We appreciate the chance to present at the Needham conference. Just as a reminder, I'll be making forward-looking statements. We encourage everybody to review our most recent 10-K filing for specifics around our risks and forward-looking statements.

So I'm very pleased to share the X4 story with you where we're focused on developing innovative treatments for rare diseases that are caused by a dysregulated immune system. The immune system is so critical in health and well-being. And there's several areas that we believe our once-daily oral can address and create dramatic impact favorably for patients in the US and worldwide, potentially treating over

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot